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Hepatitis B virus-like particles, icosahedral structures formed by multiple core protein dimers, are
promising immune-enhancing vaccine carriers for foreign antigens. Insertions into the surface-exposed
immunodominant loop are especially immunogenic. However, the need to conserve the particulate
structure to ensure high immunogenicity imposes restraints on the nature of the heterologous
sequence that can be inserted. We propose a new approach to constructing HBc particles linked to
the target epitopes that relies on non-covalent interactions between the epitope and pre-assembled
unmodiﬁed HBc particles. Interaction was enabled by fusion of the epitope to the GSLLGRMKGA
peptide, binding to the spike tips. This peptide may be used as a ‘‘binding tag’’ allowing in vitro
construction of HBc particles carrying the target peptide. Such virus-like particles carrying multiple
copies of the extracellular domain of the M2 protein of different inﬂuenza strains appeared to be highly
immunogenic and protected immunised mice against a lethal inﬂuenza challenge.
& 2012 Elsevier Inc. All rights reserved.Introduction
Virus-like particles (VLPs) built in a symmetric manner from
hundreds of viral capsid proteins could serve as molecular
carriers, providing a regular arrangement of the target peptides
on the surface of the particle (for a review see Pumpens and
Grens, 2001). Self-assembly of viral structural proteins into VLPs
mimics the formation of viral capsids. VLPs have a speciﬁc
conformation and provide a high number of introduced peptides
per particle, factors that are important for their functional activity
in inducing an immune response, binding of receptors, etc.
Virion of the hepatitis B virus (HBV) consists of an outer
envelope derived from the host cell membrane. Three distinct
but related forms of surface antigen (small, middle, and large) are
embedded in the envelope. Inside the envelope is the viral
nucleocapsid or core particle, comprising the HBV genome and
polymerase protein (Ganem, 1991). The most common form of
the HBc particle consists of 240 subunits of core protein that
assemble as dimers into a spherical particle approximately 34 nm
in diameter, with a triangulation number T¼4, carrying 120ll rights reserved.
, Russian Academy of
cow, Russia.
il.ru (N.V. Ravin).spikes (Wynne et al., 1999), each of which consists of two
interacting a-helical loops formed by the two partners of the
dimer. HBc molecules may be easily produced in a number of
heterologous expression systems, including bacteria, plants and
animal cells, and retain their ability to self-assemble into VLPs
that are easy to purify because of their particulate nature. HBc
particles possess not only an outstanding ability to induce B cell,
T helper (Th), and cytotoxic T cell (CTL) responses but also permit
the inserted polypeptides to exhibit the appropriate immuno-
logical properties (Pumpens and Grens, 2001). Therefore HBc
particles have become one of the most popular carriers for the
presentation of foreign peptides, in particular, heterologous
B- and T-cell epitopes derived from bacterial, viral, and protozoan
pathogens. In many cases the protection of experimental animals
against challenge with pathogens has been demonstrated
(Pumpens and Grens, 2001).
The most common approach used to produce HBc particles
carrying the target peptide is based on the construction of fusion
proteins by genetic engineering. A search for appropriate targets
for insertion of various foreign epitope sequences revealed three
possible points of insertion: the N- and C-termini of the HBc,
and the immunodominant loop region located at the tip of the
surface ‘‘spikes’’ on HBc particles (around codons for Asp78 and
Pro79). The N-terminal and C-terminal insertions reach a max-
imum length of 100 amino acids and inserted sequences may be
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inserted at the N- and C-termini are immunogenic, but chimeras
maintain strong intrinsic HBc immunogenicity. The highest immu-
nogenicity was observed when the epitopes were inserted into an
immunodominant loop region. Moreover, since the immune
response against HBc is mainly directed against the spikes
(Salfeld et al., 1989; Wynne et al., 1999), insertion of epitopes
within this region abrogates the intrinsic HBc immunogenicity and
targets the immune response towards the inserted sequences
(Pumpens and Grens, 2001). The capacity of the immunodominant
loop region for foreign insertions is rather high, as demonstrated
by successful insertions of the entire 238-aa green ﬂuorescent
protein (Kratz et al., 1999) and OspC protein of Borrelia burgdorferi
(Skamel et al., 2006).
However, depending on the nature of the epitope, its insertion
into HBc may reduce the stability of the recombinant particles or
even prevent their assembly (Karpenko et al., 2000; Vogel et al.,
2005). Both the N- and C-termini of an inserted peptide must ﬁt
the conformation of the HBc acceptor sites, a requirement that
is not always satisﬁed by many natively folded proteins. The
introduction of different ‘‘ﬂexible’’ linkers between the epitope
and the points of insertion may improve the stability of the
particles (Kratz et al., 1999), but obtaining recombinant VLPs for
the epitope of choice cannot be guaranteed. Another point of
concern is the propensity of an insert to form multimers, for
example, dimerising and tetramerizing colour variants of GFP
failed to form soluble VLPs while successful particle formation
was demonstrated when engineered monomeric variants were
used instead (Vogel et al., 2005).
An alternative approach relies on chemical linkage of the
epitope to unmodiﬁed HBc. For example, Jegerlehner et al.
(2002) described a M2e-HBc particle made by chemical linkage
of the M2e peptide of the inﬂuenza virus to a lysine residue
introduced into the immunodominant loop of HBc particle sub-
units. However, chemically linked peptides are randomly oriented
on the surface, making such particles less immunogenic than
‘‘genetic’’ fusions that could provide high density, highly symme-
trical, and correctly displayed inserted foreign sequences on the
surface, which would favour a vigorous immune response.
Here we suggest another approach to construct HBc particles
linked to the target epitope that relies on protein–protein inter-
action rather than genetic fusion or chemical coupling. Previously,
Dyson and Murray (1995) showed that small peptides containing
the sequence motif LLGRMK bind to the immunodominant loops
of HBc and block the interaction of core particles with the surface
antigen that is critical for HBV assembly. Later Bo¨ttcher et al.
(1998) found that the peptide GSLLGRMKGA showed the highest
afﬁnity to HBc. Here we show that this peptide may be used as a
‘‘binding tag’’, allowing in vitro construction of HBc particles
carrying the target epitope. Such VLPs, carrying multiple copies
of the extracellular domain of inﬂuenza virus M2 protein
appeared to be highly immunogenic and protected immunised
mice against a lethal inﬂuenza challenge.Fig. 1. Isolation of 3 MP–HBc protein complex using nickel afﬁnity chromato-
graphy. Protein samples were analysed by SDS-PAGE. Lane 1, molecular weight
markers (sizes shown in kD); lane 2, lysate of 3 MP-producing strain; lane 3, lysate
of HBc-producing strain; lane 4, mixture of E. coli lysates, containing HBc and 3
MP, before puriﬁcation; lane 5, proteins puriﬁed on Ni-NTA-resin from the
mixture of E. coli lysates, containing HBc and 3 MP; lane 6, proteins from 3 MP-
producing strain puriﬁed on Ni-NTA-resin; lane 7, protein extract from
HBc-producing strain puriﬁed on Ni-NTA-resin. In order to prevent aggregation
of 3 MP all protein samples except markers were treated with iodoacetamide
immediately before loading on the gel. Lys, lysosyme.Results
HBc can form stable complexes with M2e fused to the GSLLGRMKGA
peptide
The extracellular domain of the inﬂuenza virus M2 protein,
M2e, is a promising target for the development of ‘‘universal’’
vaccines against inﬂuenza (Neirynck et al., 1999; Fiers et al.,
2009). However, in order to be immunogenic it needs to be linked
to a carrier molecule such as an HBc particle. A number of genetic
fusions between M2e and HBc have been constructed (Neiryncket al., 1999; De Filette et al., 2005); notably, the most protective
particle contained three consecutive M2e copies linked to the
N-terminus of HBc (De Filette et al., 2005). Therefore we designed
two M2e-containing proteins carrying the HBc-binding peptide,
GSLLGRMKGA. The ﬁrst protein, 3 MP, contained an N-terminal
histidine tag, two copies of the M2e peptide of inﬂuenza strain
A/Duck/Potsdam1402-6/1986 (M2ep), a single copy of the M2e
peptide of inﬂuenza virus strain A/Chicken/Kurgan/05/2005
(M2ek), and GSLLGRMKGA at the C-terminus. The second protein,
2 MP, had a similar structure but contained only two copies of
M2e, both from the strain A/Duck/Potsdam1402-6/1986. The
control peptide, 3 MPn, contained an N-terminal histidine tag,
three copies of the M2e peptide as in 3 MP, but lacked the HBc-
binding peptide GSLLGRMKGA.
The calculated molecular weight of the 3 MP peptide is
10.6 kD, however, it migrate slowly in SDS-PAGE and form diffuse
bands (Fig. S1). This is probably the result of an aggregation of
M2e peptides naturally exposed on the surface of infected cells as
tetramers (Holsinger and Lamb, 1991). Western blot analysis
conﬁrmed that aggregated 3 MP is recognised by monoclonal
antibodies against M2e (Fig. S1).
In order to test whether HBc particles can form stable com-
plexes with 3 MP protein, we expressed both proteins in E. coli,
lysed the cells and combined the lysates. The 3 MP protein carries
an N-terminal 6-histidine tag and thus may be puriﬁed using
standard nickel afﬁnity chromatography, while HBc was expressed
without any tag sequences. Thus co-puriﬁcation of HBc with 3 MP
would indicate the formation of a tight complex between HBc and
3 MP. Analysis of protein samples by SDS-PAGE showed that 3 MP
may be puriﬁed on Ni-NTA-resin, but HBc alone is unable to bind
the substrate (Fig. 1). However, puriﬁcation of the mixture of E. coli
lysates, containing HBc and 3 MP, allowed the isolation of both
proteins, indicating binding of 3 MP to HBc. Similar results were
obtained when HBc was co-puriﬁed with the 2 MP protein.
Removing of the HBc-binding peptide GSLLGRMKGA from 3 MP
prevents co-puriﬁcation of HBc (Fig. S2) conﬁrming that interaction
of the target epitope with HBc is speciﬁc and depends on this
‘‘binding tag’’.
The above data conﬁrm that HBc molecules can bind to 3 MP
or 2 MP protein and form relatively tight complexes that can be
puriﬁed by nickel afﬁnity chromatography. In order to conﬁrm
Fig. 2. SDS-PAGE and Western blotting of protein preparations fractionated by ultracentrifugation.
A. HBc particles in the lysate of E. coli strain JM109/pQE60-HBc (SDS-PAGE).
B. 3 MP–HBc complex puriﬁed on Ni-NTA column (SDS-PAGE).
C. 3 MP–HBc complex puriﬁed on Ni-NTA column (Western blotting with antibodies against M2e).
Lanes 1–8, different fractions of the sucrose density gradient after ultracentrifugation, from the minimal (1) to maximal (8). Lane 9 (panels B and C), puriﬁed 3 MP–HBc
complex collected after Ni-NTA column, before ultracentrifugation. Lys, lysosyme. Protein samples were not treated with iodoacetamide.
Fig. 3. Electron microscopy analysis of 3 MP–HBc complex puriﬁed on Ni-NTA
column.
E.A. Blokhina et al. / Virology 435 (2013) 293–300 295that the HBc molecules in these complexes are assembled in VLPs,
we analysed the complexes by ultracentrifugation. Proteins from
the HBc-producing E. coli cells and 3 MP-HBc protein samples
puriﬁed on Ni-NTA column were loaded on a 10–60 % sucrose
gradient and resolved by centrifugation. We found that the 3 MP-
HBc sample was distributed between two fractions (Fig. 2). The 3
MP protein was found in the top fraction with 10% sucrose.
The second component, HBc, was found in fractions with 22–25
% sucrose, like the HBc particles present in the lysate of HBc-
producing E. coli cells. Therefore we can conclude that HBc is
present as VLPs in the complex with 3 MP. The 3 MP–HBc
complex appeared to be dissociated in the course of centrifuga-
tion in the sucrose gradient. It is sucrose that destabilises
the complex since puriﬁcation of a mixture of 3 MP and
HBc—containing E. coli lysates on Ni-NTA-resin in the presence
of 10% sucrose resulted in isolation of 3 MP protein without HBc
(data not shown).
The presence of nanosized virus-like particles with a diameter
of 30 nm in the 3 MP–HBc protein sample after Ni-NTA column
puriﬁcation was also conﬁrmed by electron microscopy (Fig. 3).
Non-covalent linkage to HBc particles increases immunogenicity
of M2e
It has been reported that genetic or chemical fusion of M2e to
HBc or other similar carriers greatly increases the immune
response against M2e (reviewed by Fiers et al., 2009 and
Schotsaert et al., 2009). Accordingly we evaluated the immune
response against ‘‘naked’’ 2 MP and 3 MP peptides and against
their complexes with HBc. Mice were vaccinated subcutaneously
on two occasions 3 weeks apart with 10 mg protein, using Titer-
Max Gold Adjuvant (Sigma) for the ﬁrst immunisation, and
incomplete Freund’s adjuvant (Sigma) for the second immunisa-
tion. Blood samples were taken 3 weeks after the ﬁrst injection
and 2 weeks after the second injection. We analysed the serum by
ELISA to identify IgG antibodies directed against M2e. To perform
ELISA, we used the synthetic peptides G19 and G11-1, whose
sequences corresponded to the M2e of inﬂuenza strains A/Duck/
Potsdam1402-6/1986 (present in two copies in 3 MP and 2 MP)and A/Chicken/Kurgan/05/2005 (present in a single copy in 3 MP
but absent from 2 MP), respectively. The results (Fig. 4) show that a
strong immune response developed in mice that were immunised
with the 3 MP–HBc sample, even after the ﬁrst immunisation.
The antibody titre in the serum increased further after the second
immunisation. The 3 MP protein was less immunogenic when it
was not linked to HBc. The same was true for the 2 MP–HBc and 2
MP pair; the latter protein appeared to be a very poor immunogen.
The 2 MP–HBc complex raised a strong immune response only
after the second immunisation. Overall the results show that:
(i) binding of the M2e peptide to the HBc carrier greatly increases
its immunogenicity, (ii) complexes containing three copies induce
a faster response than those with two copies of M2e, and (iii)
antibodies raised against M2e from one strain (2 MP–HBc sample)
can interact with the M2e peptide from another inﬂuenza strain,
suggesting the possibility of cross-protection .
The 3 MP–HBc protein complex in combination with interleukin-2
confers protection against potentially lethal inﬂuenza challenge
The above data show that immunisation of mice with the 3
MP–HBc protein complex induces the fastest and strongest
immune response, and thus this vaccine candidate was chosen
for evaluation of protection against different inﬂuenza strains.
Fig. 4. Titre of IgG antibodies against M2e upon immunisation of mice with 2 MP, 3 MP, 2 MP–HBc and 3 MP–HBc. Plates were coated with the synthetic peptides G19
or G11-1 and probed with sera of mice collected after the ﬁrst and second immunisations.
Fig. 5. Immunogenicity of 3 MP–HBc protein complex in combination with
murine IL2. Plates were coated with the M2e synthetic peptides G19 (A/Duck/
Potsdam/1402-6/1986), G11-1 (A/Chicken/Kurgan/05/2005), G26 (A/California/04/
2009) or G18 (human consensus), and probed sera of immunised mice collected at
different times (shown in days after the ﬁrst immunisation). Sera of non-
immunised mice were used as a control.
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supplemented with recombinant murine interleukin-2 (IL2),
which is known to be a powerful adjuvant (for example, Kawamura
et al., 1985; Nakao et al., 1994; Taylor, 1995). The recombinant
IL2 protein contained a polyhistidine tag and the HBc-binding
peptide GSLLGRMKGA fused to the N-terminus. It was puriﬁed by
nickel afﬁnity chromatography and added to the 3 MP–HBc
protein complex to 30% of the total protein before immunisation.
The presence of HBc-binding peptide enabled the intermolecular
association of IL2 with the HBc carrier.
Mice were vaccinated three times with 50 mg protein, using
TiterMax Gold Adjuvant (Sigma) for the ﬁrst subcutaneous
immunisation, and incomplete Freund’s adjuvant (Sigma) for the
subsequent intramuscular immunisations. The second immunisa-
tion was conducted 3 weeks after the ﬁrst, and the third was done
the following week. Sera were collected after each immunisation,
and the antibody titres were determined in the pooled sera of
mice from experimental and control groups (3–5 mice each).
A strong immune response was activated after the second
immunisation and further increased after the third (Fig. 5).
Induced antibodies efﬁciently bind to synthetic M2e peptides
G19 and G11-1, which are present in the candidate vaccine, and
to peptide G26 from ‘‘swine’’ strain A/California/04/2009, which
differs by one amino acid from G11-1 . However, the peptide G26
corresponding to the ‘‘consensus’’ M2e sequence of human
inﬂuenza strains was poorly recognised.
Immunised and control mice were challenged with 5 LD50 of
mouse-adapted inﬂuenza strains A/Duck/Potsdam/1402-6/1986
(H5N2) and A/Chicken/Kurgan/05/2005 (H5N1) of avian origin,
and ‘‘swine’’ strain A/California/04/2009 (H1N1). All immunised
mice survived the challenge with both ‘‘avian’’ strains, the M2e
sequences of which match those in the 3 MP–HBc used for
immunisation (Fig. 6). In the heterologous group, challenged with
the ‘‘swine’’ strain, in which the M2e sequence differs by 3 of 23
amino acids from M2ep and 1 of 23 amino acids from M2ek, 8 out
of 9 mice survived in contrast to 2 out of 9 mice in the control
group. The morbidity of the disease was monitored by measuringthe weight of the animals. The data presented in Fig. 6 reveal that
immunisation did not prevent morbidity but signiﬁcantly reduced
it relative to the control, especially when the animals were
challenged with ‘‘homologous’’ inﬂuenza strains.Discussion
HBc antigen is one of the most frequently used carriers for the
presentation of different target peptides, particularly epitopes.
A number of successful examples of the construction of genetic
and, more rarely, chemical fusions with HBc are known (reviewed
in Pumpens and Grens, 2001). However, the insertion of foreign
amino acid sequences in natural protein may affect its appropriate
conformation and, in the case of HBc, prevent the formation of
VLPs or reduce their stability (Karpenko et al., 2000). Such problems
Fig. 6. Protective efﬁciency of 3 MP–HBc candidate vaccine. Mice were challenged with 5 LD50 of different inﬂuenza strains; survival (left) and weight loss (right) were
monitored for 14 days post-challenge.
E.A. Blokhina et al. / Virology 435 (2013) 293–300 297most frequently occur for insertions into the immunodominant
loop region, providing the most immunogenic chimeras.
Here we suggest an alternative approach to the construction of
HBc particles carrying the desired epitopes based on binding of
the target peptides to pre-assembled HBc particles, formed by
unmodiﬁed HBc antigen. Such binding relies on protein–protein
interactions between short peptides, previously selected by
phage-display (Dyson and Murray, 1995), with the spikes exposed
on the surface of HBc particles, and essentially mimics the
interactions involved in the formation of the HBV virion. We
developed a rather simple method of assembly and puriﬁcation
of epitope–HBc complexes. Two components, HBc and the target
epitope fused to a 6-his tag at the N-terminus and to the
HBc-binding peptide GSLLGRMKGA at the C-terminus, were pro-
duced in E. coli. The complex formed upon combining two lysates,
containing the epitope and HBc particles, already assembled in vivo
in E. coli cells. The target epitope was then puriﬁed together with
bound HBc particles using nickel afﬁnity chromatography. Inter-
actions between the HBc particles and the epitope appeared to be
strong enough to allow co-puriﬁcation . However, this link may be
easily destabilised, for example, by adding sucrose. The way to
stabilise the complex and make it more suitable for handling
remains to be investigated.
For the proof of principle we produced HBc particles carrying
the M2e peptides of inﬂuenza virus and evaluated these VLPs
as a candidate vaccine against inﬂuenza. Unlike haemagglutinin
and neuraminidase, M2e, the extracellular domain of the inﬂu-
enza virus M2 protein, is well conserved in most inﬂuenza
isolates of human origin, which makes it an attractive target for
the development of broad-spectrum vaccines against inﬂuenza(Fiers et al., 2009). However, the creation of M2e-based vaccines
is hindered by the low immunogenicity of this protein (Feng et al.,
2006). This problem can be solved by the fusion of M2e to a virus-
like carrier particle either genetically by the creation of a hybrid
protein or through chemical cross-linking . M2e epitopes linked to
subunits of VLPs are then seen by the immune cells as a dense
array of peptides, which is optimal for a vigorous immune
response (Bachmann et al., 1993). Besides HBc, virus-like particles
based on human papilloma virus (Ionescu et al., 2006; Matic´ et al.,
2011), bacteriophage Qb (Bessa et al., 2008), papaya mosaic virus
(Denis et al., 2008), and cow pea mosaic virus (Meshcheryakova
et al., 2009) can be used as M2e carrier particles. Since the
pioneering work of Neirynck et al., 1999, a number of M2e–HBc
genetic fusions have been constructed. M2eHBc particles may
be produced in different expression systems including E. coli
(Neirynck et al., 1999) and plant cells (Ravin et al., 2012). The
M2e epitope was included either in the immunodominant loop
region or at the N-terminus of HBc (De Filette et al., 2005). In the
latter case insertion of up to three consecutive copies of M2e did
not impair VLP formation; moreover, these particles activated the
more efﬁcient immune response relative to single copy insertions
and protected mice against a lethal inﬂuenza challenge (De Filette
et al., 2005). However, insertions of multiple copies of M2e into
the immunodominant loop of HBc, expected to be the most
immunogenic fusions, to our knowledge have not been reported.
Using our approach based on protein–protein interactions
between the spikes of HBc particles and the target epitope, we
produced two types of M2e-carrying HBc particles, carrying two
(2 MP) or three (3 MP) consecutive copies of M2e peptides.
Consistent with the results obtained for genetic fusions, we found
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M2e peptide by itself. Complexes containing three copies induced
a faster and stronger immune response than those containing two
copies of M2e. Therefore complex 3 MP–HBc was chosen for
further challenge tests. In order to enforce its immunological
potential the complex was supplemented with murine interleu-
kin-2, which is known to be an efﬁcient adjuvant, stimulating
a Th1-type cellular immune response (Taylor, 1995). The ‘‘modular’’
structure of the complex allowed us simply to add puriﬁed
recombinant IL2 carrying the HBc-binding peptide to pre-
assembled 3 MP–HBc . Likewise other functional peptides may
be easily included in the vaccine. We found that immunisation of
mice with 3 MP–HBc and IL2 induced a strong immune response
against M2e and provided protection against a lethal challenge
with inﬂuenza A virus.
The possibility of constructing VLPs carrying multiple copies of
M2e peptides is also important in view of the goal to develop a
‘‘universal’’ inﬂuenza vaccine that would last for several years and
was a key reason for focusing on M2e. It is well known that the
M2e sequence is conserved in almost all inﬂuenza strains isolated
from humans (Ito et al., 1991; Neirynck et al., 1999). However,
this is not true for newly emerging inﬂuenza strains of animal
origin such as the inﬂuenza A virus of the H1N1 subtype of swine
origin that caused the 2009–2010 pandemic and highly patho-
genic strains of the avian inﬂuenza H5N1 that caused hundreds of
cases of illness and lethal outcomes several years ago. The
sequences of M2e peptides of such strains differ signiﬁcantly
from the human consensus, suggesting that a speciﬁc M2e-based
vaccine against these strains would be required. Fan et al. (2004)
showed that the antibodies raised against M2e peptides derived
from human inﬂuenza strains did not react with the M2e peptides
of avian H5N1 virus. Previously we found that immunisation of
mice with HBc particles carrying the M2e peptide of the ‘‘swine’’
inﬂuenza virus A/California/04/2009(H1N1) on its N-terminus
completely protected mice against infection with this virus strain
but conferred only partial protection against avian strains and
did not protect against ‘‘human‘‘ inﬂuenza strain A/PR/8/34
(Kotlyarov et al., 2010). Likewise here we found that antibodies
induced by immunisation of mice with 3 MP–HBc particles
efﬁciently bind to ‘‘homologous’’ M2e peptides of avian strains,
which are included in 3 MP, but not to ‘‘human consensus’’ M2e
peptide. Therefore, the simultaneous presentation of M2e pep-
tides from several important strains on the HBc carrier particle
could be required for the development of a broad-spectrum
vaccine. Here we show that the immunisation of mice by 3 MP–
HBc particles confers complete protection against lethal challenge
by both inﬂuenza strains containing the M2e used in the vaccine
and about 90% protection in the case of ‘‘swine’’ strain, the M2e of
which differs by only a single amino acid residue relative to the
M2e included in the candidate vaccine.Materials and methods
Construction of expression vectors
Plasmid pQE30 was used to construct vectors for the expres-
sion of hybrid proteins comprising two or three copies of the
extracellular domain of the inﬂuenza virus M2 protein (M2e) and
mouse interleukin-2 (IL2).
The ﬁrst synthetic gene was designed to encode the hybrid
protein 3 MP, consisting of two copies of the M2e peptide of
inﬂuenza strain A/Duck/ Potsdam1402-6/1986 (M2ep), a single
copy of the M2e peptide of inﬂuenza virus strain A/Chicken/
Kurgan/05/2005 (M2ek) and the HBc-binding peptide GSLLG-
RMKGA. The synthetic sequence contained restriction sites forPstI and SalI between the M2e coding sequences (arranged as
M2ep-PstI-M2ek-SalI-M2ep) and sites for BamHI and KpnI at the
5’ and 3’ ends, respectively. Cloning of this gene at the BamHI and
KpnI sites of pQE30 resulted in the construction of expression
vector pQE30-3 MP, which allowed the production of the hybrid




Another synthetic gene was designed to encode the control
peptide, 3 MPn, containing three copies of the M2e peptide as in 3
MP, but lacking the HBc-binding peptide GSLLGRMKGA. Cloning
of this gene in pQE30 resulted in the construction of expression
vector pQE30-3 MPn.
The hybrid gene 2 MP designed for expression of the hybrid
protein 2 MP, consisting of two copies of M2ep and the HBc-
binding peptide GSLLGRMKGA, was derived from 3 MP following
deletion of the central fragment encoding M2ek by digestion with
PstI and SalI, treatment of the ends by T4 DNA polymerase and
ligation. Cloning of this gene at the BamHI and KpnI sites of pQE30
resulted in the construction of expression vector pQE30-2 MP.
For the expression of murine interleukin-2 the corresponding
synthetic gene encoding the HBc-binding peptide GSLLGRMKGA
linked to the amino acid sequence of interleukin-2 was cloned at
the BamHI and KpnI sites of pQE30. The recombinant vector
pQE30-IL2 allowed the production of the IL2 fusion protein with a
N-terminal histidine tag.
A truncated HBc gene (coding for HBc lacking the arginine-rich
C-terminal domain, amino acids 1 through 148) was modiﬁed by
PCR to contain a single C-terminal cysteine and cloned into pQE60
to generate the plasmid pQE60-HBc, which expresses HBc with-
out a histidine tag.
Expression of recombinant proteins
For the expression of recombinant proteins the corresponding
vectors were introduced into E. coli strains DLT1270 (pQE30-3 MP,
pQE30-3 MPn, pQE30-2 MP and pQE30-IL2) or JM109 (pQE60-
HBc). The strains were grown in LB until the midpoint of the
logarithmic growth phase (OD600¼0.5) at 37 1C, then IPTG was
added to 1 mM and the culture was grown for another 4–5 h
at 37 1C (for pQE30-3 MP, pQE30-3 MPn and pQE30-2 MP) or for
16–18 h at 30 1C (for pQE30-IL2 and pQE60-HBc).
After induction the bacteria were collected by centrifugation
and resuspended in phosphate buffer, pH 7.2, supplemented with
0.15 M NaCl (PBS). This suspension was treated with 1 mg/ml
lysozyme for 15 min on ice followed by sonication. The suspen-
sions were then centrifuged for 5 min at 13,000 g. The super-
natants (‘‘lysates’’) were used for the puriﬁcation of 3 MP, 3 MPn
and 2 MP proteins or complexes formed by these proteins and HBc.
Puriﬁcation of 3 MP and 2 MP proteins
Before puriﬁcation the pH of the ‘‘lysate‘‘ solution was adjusted
to 7.2 using Na2HPO4 and imidazole was added to 20 mM. The
solution was then applied to Ni-NTA-resin equilibrated with PBS
containing 20 mM imidazole and incubated for 30 min. Following
binding of the target protein, the resin was washed with PBS
containing 20 mM imidazole. The protein was eluted with PBS
containing 0.5 M imidazole and dialysed against PBS.
Puriﬁcation of interleukin-2
Following the lysis of the induced cells and centrifugation of the
suspension as described above, the pellet containing interleukin-2
(IL2) was solubilised in PBS containing 6 M guanidine hydrochloride
Table 1
Amino acid sequences of M2e peptides.
Inﬂuenza strain Origin Synthetic peptide M2e sequence
A/Duck/Potsdam/1402-6/1986 Avian G19 SLLTEVETPTRNGWECKCSDSSD
A/Chicken/Kurgan/05/2005 Avian G11-1 SLLTEVETPTRNEWECRCSDSSD
A/California/04/2009 Swine/ human G26 SLLTEVETPTRSEWECRCSDSSD
Most human strains Human G18 SLLTEVETPIRNEWGCRCNDSSD
E.A. Blokhina et al. / Virology 435 (2013) 293–300 299and 20 mM imidazole. The solution was centrifuged for 5 min at
13,000 g and the supernatant was collected. The His-tagged IL2 was
bound to Ni-nitrilotriacetic acid (NTA) resin (Promega) equilibrated
with PBS containing 6 M guanidine hydrochloride and 20 mM
imidazole. Following protein binding, the resin was washed ﬁrst
with the same solution and then with PBS containing 20 mM
imidazole. The protein was eluted with PBS containing 10% arginine
and 0.5 M imidazole. The eluate was immediately dialysed against
PBS. Upon removal of the insoluble material by centrifugation,
about 50% of puriﬁed IL2 remained in the solution.
Binding of M2e peptides to HBc and puriﬁcation of protein complexes
The E. coli lysates containing 3 MP, 3 MP* or 2 MP peptides were
mixed with an equal volume of the HBc-containing lysate. The pH
of the solution was adjusted to 7.2 using Na2HPO4 and imidazole
was added to 20 mM. The solution was incubated for 1 h at room
temperature with periodic mixing, or incubated overnight at
þ6 1C. Then the solution was applied to Ni-NTA-resin equilibrated
with PBS containing 20 mM imidazole and incubated for 30 min.
Following binding of the complex, the resin was washed with PBS
containing 20 mM imidazole. The protein complex was eluted with
PBS containing 0.5 M imidazole and dialysed against PBS. The
purity and composition of the puriﬁed protein complexes were
analysed by SDS-PAGE and ultracentrifugation.
Treatment of protein samples with iodoacetamide before SDS-PAGE
In order to prevent disulﬁde-bond mediated aggregation of
M2e-containing proteins resulted in their migration as diffuse
high-molecular bands in SDS-PAGE, the protein samples were
treated with the alkylating agent iodoacetamide (Lane, 1978).
Proteins were incubated in solution containing 375 mM Tris pH
8.8, 15% glycerol, 6 M urea, 2% SDS and 2% dithiothreitol for
15 min at 50 1C, then iodoacetamide was added to 2.5% and the
incubation was continued for other 15 min. Upon incubation the
samples were supplemented with 0.01% bromophenol blue dye
and immediately loaded on a gel. Iodoacetamide treatment was
performed for protein samples analysed by SDS-PAGE as shown in
Figs. 1 and S2.
Sucrose gradient ultracentrifugation
About 12-millilitre polyallomer tubes were ﬁlled with 10 ml of
a linear sucrose gradient (10–60%) in PBS pH 7.2. Then 2 ml of
sample (lysate or puriﬁed protein) was layered at the top of each
tube. Centrifugation was performed in a SW40 rotor in an Optima
L-90K Ultracentrifuge (Beckman Coulter, USA) at 35,000 rpm,
at 10 1C for 4 h. The gradients were drained by pipetting 0.5-ml
fractions and subjected to protein analysis.
Electron microscopy
Specimens were prepared by routine negative contrasting using
1% uranyl acetate solution, examined in a JEM-1011 transmission
electron microscope (JEOL, Japan), and photographed using a Moradadigital camera (Olympus-SIS) at the magniﬁcation calibrated by the
diffraction lattice.
Synthetic peptides
The synthetic peptides G19, G11-1, G26 and G18, corres-
ponding to the M2e of different inﬂuenza strains, were used
as a standard for the determination of antibodies against M2e
(Table 1).
Analysis of production of antibodies against M2e
Balb/c mice weighing 18–20 g was used for immunisation
experiments. For serum preparations blood samples were
obtained from mice 3 weeks after the ﬁrst and 2 weeks after the
second or third immunisation. Equal volumes of sera obtained
from different mice (3–5 mice) were ‘‘pooled’’ for the analysis of
antibody production. The serum of non-immunised mice was
used as a negative control. Monoclonal antibodies to the M2e
peptide strain A/Duck/Potsdam/1402-6/1986 (H5N2) were used
as a positive control.
For ELISA, 96-well plates with a high sorption capacity
(Greiner, Germany) were covered with synthetic peptides G11-1,
G19, and G26 at a concentration of 5 mg/ml (in carbonate buffer,
pH 9.5–9.6) and kept overnight at 4 1C. Plates were treated with a
blocking buffer (0.01 M PBS pH 7.2–7.4) supplemented with 5%
foetal calf serum for 1 h at room temperature and washed three
times using PBS with Tween. The pooled mice sera from each
group were analysed in duplicate. A series of 1:2 dilutions of the
different serum samples, starting with a 1:200 dilution, were
loaded onto the antigen-coated plates in the blocking buffer and
then incubated for 1 h at room temperature. As a conjugate,
rabbit polyclonal anti-mouse IgG (Abcam, Great Britain) was used
at a 1:8000 dilution, after labelling with a horseradish peroxidase.
TMB was used as a substrate. The reaction was monitored by
measuring the OD at 450 nm. The endpoint titres are deﬁned as
the highest dilution producing an OD value twice that of the
background (serum of non-immunised mice).
Inﬂuenza viruses and challenge
The following mouse-adapted inﬂuenza viruses were used to
challenge animals immunised by the candidate vaccines: A/Duck/
Potsdam/1402-6/1986(H5N2), A/Chicken/Kurgan/05/2005 (H5N1)
and A/California/04/2009 (H1N1). Mice were challenged 56 days
after the ﬁrst immunisation. The virus was administered intrana-
sally in a total volume of 50 ml containing 5LD50 to mice anaes-
thetised by ether. The animals were observed daily after infection.
Mortality was monitored on a daily basis for 2 weeks. Morbidity
was assessed by body weight.Acknowledgements
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